Stockholm, November 23, 2023 - Intervacc AB (publ) has at the request of a group of shareholders, which together control not less than one-tenth of all shares in the company, on 23 November 2023 held an Extraordinary ... Read more
Stockholm, November 22, 2023 – Intervacc AB (“Intervacc”) announces that the United States Patent and Trademark Office has granted an approval for Intervacc’s patent application in the United States for a vaccine ... Read more
Sales of Strangvac® are still low, but higher sales have been noted in recent months.
The Group in summary
The composition of the Nomination Committee has been determined, Intervacc announced today that the Nomination Committee consists of the following persons who together represent approximately 16,6 percent of the number ... Read more
At the request of a group of shareholders which together control not less than one-tenth of all shares in Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), the shareholders are hereby invited to an ... Read more
We have the great pleasure of welcoming Agneta Gustafsson to Intervacc and our initiative - Together against strangles. Agneta, who is a well-established name in the veterinary medicine industry, has renowned specialist ... Read more